IDH2 and central nervous system cancer: Furthermore, 90% of IDH-mutated gliomas harbor a point mutation in IDH1 R132H, which can be identified with immunohistochemistry methods, a simple and reproducible method that can be performed in the vast majority of pathology departments, but for the 10% of patients with IDH2 mutation, molecular techniques are not available in most hospitals14.